Navigation Links
Asia-Pacific Nuclear Medicine Market was Valued at $500.8 Million in 2012 and is Poised to Reach $824.9 Million by 2017 at a CAGR of 10.5% - New Report by MarketsandMarke
Date:6/17/2013

(PRWEB) June 17, 2013

The "Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market & Stable Isotopes [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Forecast to 2017 " analyzes and studies the major market drivers, restraints, and opportunities in Japan, China, India, South Korea, Indonesia, Malaysia, Australia, New Zealand, & rest of Asia.

Browse:

  • 146 Market Data Tables
  • 27 Figures
  • 313 Pages and In-Depth Table of on “Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market

http://www.marketsandmarkets.com/Market-Reports/asia-pacific-nuclear-medicine-radiopharmaceuticals-market-1140.html

Early buyers will receive 10% customization on this report.

This report studies the Asia-Pacific nuclear medicine market over the forecast period of 2012-2017.

Asia-Pacific Nuclear Medicine / Radiopharmaceuticals Market was valued at $500.8 million in 2012 and is poised to reach $824.9 million by 2017 at a CAGR of 10.5%.

Similar to the global nuclear medicine market, the Asia-Pacific region is also minimizing its dependency on nuclear reactor by introducing hospital-based cyclotron facilities. This paves the way for novel isotopes such as Tl-201, F-18, and Rb-82 to capitalize on opportunities in the growing diagnostics market. Besides the gigantic Tc-99m market, florbetapir F 18 and F18-FDG are gaining popularity through their applications for Alzheimers disease and diagnosis of brain tumors. Nihon Medi Physics, Covidien, Fujifilm, and ANSTO contributed more than 75 % to the APAC radiopharmaceuticals market in 2012.

It is estimated that Tc-99m diagnostic procedures are expected to increase by more than 30% in the developing markets of the Asia-Pacific region, including India, Australia, and South Korea, between 2010 and 2030. The scheduled shutdown of the NRU reactor in Canada in 2016 and OSIRIS in France in 2018 will not have any major impact in the near future, since demand in this geographic region is compensated by local reactors such as ANSTO. Radiopharmaceuticals are under clinical trials to extend applications. For instance, preference for radiopharmaceuticals in neurological indications such as Alzheimers, Parkinsons, and dementia are increasing besides conventional applications such as cardiology and oncology. Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications.

Japan is the dominant market for diagnostic radioisotopes with almost 40% share and has around 1,600 gamma cameras, installed in about 1120 institutions; PET diagnosis has increased dramatically after 2002. The total number of PET institutes in Japan has increased around 6-7 times in the last 10 years. Among Asia-Pacific countries, India, South Korea, and Australia will be significant markets due to rising healthcare budgets and increasing popularity of different radiopharmaceuticals in various clinical indications.

Processors such as ANSTO and other players from different geographies run reactors that are involved in the irradiation of U-235 to make crude isotopes. They follow various strategies to achieve sustainable growth, one of which is shifting to Low Enriched Uranium (LEU) from High Enriched Uranium(HEU).

These key players were mainly involved in strategic agreements and contracts with other institutes and players, while generator manufacturers followed several strategies to maintain a sustainable supply chain.

Asia-Pacific held the largest share in the global stable isotopes market in 2012. The stable isotopes market was estimated at $56.1 million in 2012 and is poised to grow at 12.6% CAGR over the next five years. Growth of the stable isotope market is driven by proteomics and system biology research and applications such as Nuclear Magnetic Resonance (NMR) and Mass Spectrometry (MS).

Buy a copy of this report @ http://www.marketsandmarkets.com/Purchase/purchase_report1.asp?id=1140.

Find related Reports@ Pharmaceuticals Market.

About MarketsandMarkets

MarketsandMarkets (M&M) is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world. MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services.

M&M covers thirteen industry verticals; including advanced materials, automotive and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, and telecommunications and IT.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Contact:
Mr. Rohan
North - Dominion Plaza,
17304 Preston Road,
Suite 800, Dallas, TX 75252
Tel: +1-888-6006-441
Email: sales(at)marketsandmarkets(dot)com
Connect with us on LinkedIn
Connect with us on Facebook

Read the full story at http://www.prweb.com/releases/asia-pacific-nuclear/medicine-market/prweb10839447.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Asia-Pacific Seasonal Influenza Vaccine Market to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity : MarketResearchReports.biz
2. Registration opens for Asia-Pacifics largest medical conference on osteoporosis
3. Asia-Pacific Gesture Recognition & Touchless Sensing Market is Growing at a CAGR of 83.18% & to Reach $4.18 Billion By 2018 - New Report by MarketsandMarkets
4. Global Critical Care Market Will Reach $3.2 Billion in 2019 - Growth from Factor Concentrates, New Indications and Increasing Demand for Albumin in Asia-Pacific
5. Asia-Pacific Leads in Consumption of Urea Formaldehyde Resins Followed by Europe and North America - New Report by MarketsandMarkets
6. North America Holds Major Microspheres Market Share Followed By Europe & Eurasia and The Asia-Pacific Says New Market Research Report by MarketsandMarkets
7. Piramal imaging to present data at Society for Nuclear Medicine Annual Meeting
8. Breast cancer risk estimates increased with repeated prior ct and nuclear imaging
9. Springer launches new journal with the Italian Association of Nuclear Medicine and Molecular Imaging
10. In fight against cancer, a closer look at nuclear blebbing
11. American Crane sponsors "Diary of a Nuclear Tourist"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... ... institution’s inaugural K-20 Education Summit to be held March 23-25, 2017 in Tampa, ... Jan. 25, 2017. , The keynote speakers include Dr. Michelle R. Weise, executive ...
(Date:1/23/2017)... ... ... Wooden and plastic balance boards have been around since at least the 1950s and are ... the first and only balance board to use a patent-pending design featuring high-pressure inflation technology ... time as well as skill-level adjustable for all ages and abilities. The board can ...
(Date:1/23/2017)... SC (PRWEB) , ... January 23, 2017 , ... ... is the premiere organization in North America for the scientific development, healthcare training ... 2017 Annual Scientific Session, and its 2017 AAT Member Certification Qualification Courses for ...
(Date:1/23/2017)... ... January 23, 2017 , ... Moisture ... choosing the right method is paramount to success. Selecting an inappropriate measurement method ... where multiple persons use the same equipment. Rare or expensive substances are wasted ...
(Date:1/23/2017)... ... January 23, 2017 , ... Old School Labs™, makers ... Mr. Olympia Classic Physique bodybuilder Breon Ansley to its growing team of brand ambassadors. ... bodybuilder in 2012 and in less than a year was able to turn professional, ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 2017 NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical collaboration agreement with the Children,s Hospital of ... M.D., a US key opinion leader in the mitochondrial medicine ... ... from NeuroVive,s research program, NVP015, in certain experimental disease models. ...
(Date:1/21/2017)... Research and Markets has announced the addition of ... Test (Tumor, Clinical Chemistry, Microbiology, Esoteric), By Type of Lab ... Cancer, HIV/AIDS etc.), Forecast to 2022" report to their ... ... especially clinical lab testing, which has evolved as a major ...
(Date:1/21/2017)... CAMBRIDGE, Mass. , Jan. 20, 2017 ... the Keystone Symposia Conference, "PI3K Pathways in ... Pharmaceuticals, Inc. (NASDAQ: INFI ... oral immuno-oncology development candidate that selectively inhibits ... is able to help overcome resistance to ...
Breaking Medicine Technology: